These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 752907

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD, Delgado MR.
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
    Selby G.
    Clin Exp Neurol; 1989; 26():129-39. PubMed ID: 2701877
    [Abstract] [Full Text] [Related]

  • 9. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M, Riopelle R, Libman I, Bouchard S.
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, Reid WG, Broe GA.
    Med J Aust; 1987 Feb 16; 146(4):195-8. PubMed ID: 3553878
    [Abstract] [Full Text] [Related]

  • 13. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK, Verma S, Cordingley GJ, Harris RI.
    Pharmatherapeutica; 1985 Feb 16; 4(2):132-40. PubMed ID: 4059292
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A.
    J Med Assoc Thai; 2004 Nov 16; 87(11):1293-300. PubMed ID: 15825702
    [Abstract] [Full Text] [Related]

  • 15. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB.
    Ann Neurol; 1978 Apr 16; 3(4):319-24. PubMed ID: 666273
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
    Frattola L, Albizzati MG, Spano PF, Trabucchi M.
    Nouv Presse Med; 1978 Apr 16; 5(28):1761. PubMed ID: 958891
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.